[
  {
    "ts": null,
    "headline": "Guggenheim Reiterates a Hold on Johnson & Johnson (JNJ)",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best drug stocks to buy right now. On September 10, Guggenheim analyst Vamil Divan reiterated a Hold rating on Johnson & Johnson (NYSE:JNJ) and set a price target of $167.00. The rating update followed Johnson & Johnson’s (NYSE:JNJ) announcement on September 9 that the U.S. Food and Drug […]",
    "url": "https://finnhub.io/api/news?id=c6728e007507f4c53363a0e92ce50c43077d9450f67b02fc46752dc0ffe8d04d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052688,
      "headline": "Guggenheim Reiterates a Hold on Johnson & Johnson (JNJ)",
      "id": 136782161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best drug stocks to buy right now. On September 10, Guggenheim analyst Vamil Divan reiterated a Hold rating on Johnson & Johnson (NYSE:JNJ) and set a price target of $167.00. The rating update followed Johnson & Johnson’s (NYSE:JNJ) announcement on September 9 that the U.S. Food and Drug […]",
      "url": "https://finnhub.io/api/news?id=c6728e007507f4c53363a0e92ce50c43077d9450f67b02fc46752dc0ffe8d04d"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Lifts PT for Johnson & Johnson (JNJ), Keeps Outperform Rating",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to $195 and kept an Outperform rating. Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence […]",
    "url": "https://finnhub.io/api/news?id=0420bf01d20da5f448ded22a23ae1da3d6521b05ae6f7f1a4aa22422bcedd862",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052245,
      "headline": "Wolfe Research Lifts PT for Johnson & Johnson (JNJ), Keeps Outperform Rating",
      "id": 136782162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to $195 and kept an Outperform rating. Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence […]",
      "url": "https://finnhub.io/api/news?id=0420bf01d20da5f448ded22a23ae1da3d6521b05ae6f7f1a4aa22422bcedd862"
    }
  },
  {
    "ts": null,
    "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
    "summary": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
    "url": "https://finnhub.io/api/news?id=a9cc0127fb52e5bad111cbe0fae4993c98de24e14a4e6477842edd38fbb9d840",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758049260,
      "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
      "id": 136803527,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
      "url": "https://finnhub.io/api/news?id=a9cc0127fb52e5bad111cbe0fae4993c98de24e14a4e6477842edd38fbb9d840"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ)’s Dividend Legacy: How a Healthcare Giant Built a Record of Consistent Dividends",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Johnson & Johnson (NYSE:JNJ) is an American multinational pharmaceutical, biotech, and medical technologies company. It has a highly diversified business with a wide range of medicines in its pharmaceutical division. Key growth drivers include cancer treatments Darzalex and Erleada, […]",
    "url": "https://finnhub.io/api/news?id=93d147d08eed4ddc798eb7747ace335ffdfb74cf5ffdfc685e21a197785d817d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758035372,
      "headline": "Johnson & Johnson (JNJ)’s Dividend Legacy: How a Healthcare Giant Built a Record of Consistent Dividends",
      "id": 136773284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Johnson & Johnson (NYSE:JNJ) is an American multinational pharmaceutical, biotech, and medical technologies company. It has a highly diversified business with a wide range of medicines in its pharmaceutical division. Key growth drivers include cancer treatments Darzalex and Erleada, […]",
      "url": "https://finnhub.io/api/news?id=93d147d08eed4ddc798eb7747ace335ffdfb74cf5ffdfc685e21a197785d817d"
    }
  },
  {
    "ts": null,
    "headline": "Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards",
    "summary": "ATLANTA, September 16, 2025--Lowe’s Companies, Dow, American Express, ConocoPhillips, and AIG secured top honors in the 2025 U.S. Transparency Awards announced today by Labrador Transparency, a leading global communications firm specializing in transparent corporate disclosure documents. The rankings are determined through a rigorous evaluation of corporate disclosure documents and celebrate companies dedicated to building investor and stakeholder trust through clear, concise, and effective comm",
    "url": "https://finnhub.io/api/news?id=75420e9be9f7e8461d4b1bd23b0c1d423e6d18e68108fe32d20c23c76dac3867",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758029340,
      "headline": "Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards",
      "id": 136773502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ATLANTA, September 16, 2025--Lowe’s Companies, Dow, American Express, ConocoPhillips, and AIG secured top honors in the 2025 U.S. Transparency Awards announced today by Labrador Transparency, a leading global communications firm specializing in transparent corporate disclosure documents. The rankings are determined through a rigorous evaluation of corporate disclosure documents and celebrate companies dedicated to building investor and stakeholder trust through clear, concise, and effective comm",
      "url": "https://finnhub.io/api/news?id=75420e9be9f7e8461d4b1bd23b0c1d423e6d18e68108fe32d20c23c76dac3867"
    }
  },
  {
    "ts": null,
    "headline": "Insulet names new CFO; Dexcom CEO on leave",
    "summary": "Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.",
    "url": "https://finnhub.io/api/news?id=b3216ecadec11dae3881dddea73f8e9c0eb4ce0a0a8ae2e75808261061f1246b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758026203,
      "headline": "Insulet names new CFO; Dexcom CEO on leave",
      "id": 136773285,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.",
      "url": "https://finnhub.io/api/news?id=b3216ecadec11dae3881dddea73f8e9c0eb4ce0a0a8ae2e75808261061f1246b"
    }
  },
  {
    "ts": null,
    "headline": "Medical device maker Insulet taps industry veteran Flavia Pease as CFO",
    "summary": "Insulet also said it expects to exceed its previous third-quarter total revenue forecast of 22% to 25%, driven by strong new customers for its wearable insulin pumps in both U.S. and international markets.  Pease, an industry veteran, had held the role of finance chief at contract research firm Charles River Laboratories for three years.",
    "url": "https://finnhub.io/api/news?id=7be137b16b27cf406267f578d34b21cd40708bb9da11b77d3ce6c9ef26160a57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758025509,
      "headline": "Medical device maker Insulet taps industry veteran Flavia Pease as CFO",
      "id": 136773286,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Insulet also said it expects to exceed its previous third-quarter total revenue forecast of 22% to 25%, driven by strong new customers for its wearable insulin pumps in both U.S. and international markets.  Pease, an industry veteran, had held the role of finance chief at contract research firm Charles River Laboratories for three years.",
      "url": "https://finnhub.io/api/news?id=7be137b16b27cf406267f578d34b21cd40708bb9da11b77d3ce6c9ef26160a57"
    }
  },
  {
    "ts": null,
    "headline": "Fosun's Henlius in talks with Johnson & Johnson, Roche on cancer drug",
    "summary": "Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar with the matter said. An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical at least several hundred million dollars up front and then more in milestone payments down the road based on the drug's performance, the people said. They asked not to be identified because the discussion",
    "url": "https://finnhub.io/api/news?id=cb28f1003bdb1a915fbd9658eb428bd8c049fa55885801def5bfeadacb4fc0f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758018600,
      "headline": "Fosun's Henlius in talks with Johnson & Johnson, Roche on cancer drug",
      "id": 136773287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar with the matter said. An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical at least several hundred million dollars up front and then more in milestone payments down the road based on the drug's performance, the people said. They asked not to be identified because the discussion",
      "url": "https://finnhub.io/api/news?id=cb28f1003bdb1a915fbd9658eb428bd8c049fa55885801def5bfeadacb4fc0f4"
    }
  }
]